Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

5.0%

1 terminated/withdrawn out of 20 trials

Success Rate

90.9%

+4.4% vs industry average

Late-Stage Pipeline

5%

1 trials in Phase 3/4

Results Transparency

0%

0 of 10 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 2
4(33.3%)
Phase 1
3(25.0%)
N/A
2(16.7%)
Early Phase 1
2(16.7%)
Phase 4
1(8.3%)
12Total
Phase 2(4)
Phase 1(3)
N/A(2)
Early Phase 1(2)
+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (20)

Showing 20 of 20 trials
NCT06611306Not ApplicableNot Yet Recruiting

BEAT-Breast: Trial of DE-iPTV in Patients With Primary Breast Cancer With Brain Metastases Who Are Not Suitable for Stereotactic Radiotherapy.

Role: collaborator

NCT06590506Recruiting

High Definition Medicine for Solid Tumors Oncology

Role: lead

NCT01560663Unknown

Predictors of Response to Neoadjuvant Docetaxel-Carboplatin Chemotherapy for Patients With Stage II and III Triple Negative Breast Cancer

Role: collaborator

NCT04197089Phase 4Completed

Biological Effect of Vitamin D in Patients With Urothelial Carcinoma

Role: collaborator

NCT04346147Phase 2Unknown

Clinical Trial to Evaluate Efficacy of 3 Types of Treatment in Patients With Pneumonia by COVID-19

Role: collaborator

NCT02802098Early Phase 1Completed

Abrogation of Chronic Monoclonal Antibody Treatment-induced T-cell Exhaustion With DURVALUMAB in Advanced HER-2 Negative Breast Cancer

Role: lead

NCT01548924Phase 1Terminated

Determination of Dose of Antiangiogenic Multitargeted DOVITINIB (TKI258) Plus Paclitaxel in Patients With Solid Tumors

Role: lead

NCT04259879Not ApplicableCompleted

Molecular Pathways Related to Short-term Fasting Response

Role: collaborator

NCT01484080Phase 1Completed

Neoadjuvant Paclitaxel Versus BIBF 1120 Priming Followed by BIBF 1120 Plus Paclitaxel in Early HER-2 Negative Breast Cancer With Proteomic and Dynamic Imaging Correlates

Role: lead

NCT02922218Unknown

PROSENZA: Prospective Multi-Centre Study of Prognostic Factors in mCRPC Patients Treated With Enzalutamide.

Role: lead

NCT02925702Unknown

PRORADIUM: Prospective Multi-centre Study of Prognostic Factors in mCRPC Patients Treated With Radium-223.

Role: lead

NCT02362620Unknown

PROSTAC: Prospective Multi-centre Study of Prognostic Factors in mCRPC Patients Treated With Docetaxel or Cabazitaxel.

Role: lead

NCT02787837Unknown

PROSABI: Prospective Multi-centre Study of Prognostic Factors in mCRPC Patients Treated With Abiraterone Acetate.

Role: lead

NCT02619162Phase 1Completed

Nintedanib+Letrozole in Postmenopausal Women With Breast Cancer: Clinical Trial Safety and Pharmacodynamics

Role: lead

NCT02806817Early Phase 1Completed

ME-344 in Early HER2-negative Breast Cancer With Antiangiogenic-induced Mitochondrial Metabolism

Role: lead

NCT03075735Completed

Prospective Multicentre Cohort Study PROREPAIR-B (mCRPC)

Role: lead

NCT02928432Phase 2Completed

SWITCH: Study of the Prednisone to Dexamethasone Change in mCRPC Patients Treated With Abiraterone

Role: lead

NCT01703910Phase 2Completed

Study of Individualized Therapies Selection for Patients With Metastatic Colorectal Carcinoma According to the Therapeutic

Role: lead

NCT01454180Phase 2Completed

Study of Individualized Selection of Chemotherapy in Patients With Advanced Pancreatic Carcinoma According to Therapeutic Targets

Role: lead

NCT01779583Unknown

Circulating Exosomes As Potential Prognostic And Predictive Biomarkers In Advanced Gastric Cancer Patients ("EXO-PPP Study")

Role: collaborator

All 20 trials loaded